Related references
Note: Only part of the references are listed.Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol
K. P. Kanebratt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study group
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
R. S. Midgley et al.
ANNALS OF ONCOLOGY (2007)
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors
Ignacio Duran et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: A phase II study of the Southwest Oncology Group
Christopher W. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer
Jared A. Gollob et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts)
C. W. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer
Alex A. Adjei et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma
Bernard Escudier et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib
K. Mross et al.
EUROPEAN JOURNAL OF CANCER (2007)
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
Dirk Strumberg et al.
ONCOLOGIST (2007)
Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4
Ylva Bottiger
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
H Richly et al.
ANNALS OF ONCOLOGY (2006)
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
C Lathia et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer
LL Siu et al.
CLINICAL CANCER RESEARCH (2006)
Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan:: sources of variability and predictors of adverse effects in 419 healthy subjects
C Funck-Brentano et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients
ER Lepper et al.
CLINICAL CANCER RESEARCH (2005)
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance
S Borges et al.
DRUG METABOLISM AND DISPOSITION (2005)
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer
ML Veronese et al.
BRITISH JOURNAL OF CANCER (2005)
CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy
M Wong et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicities
WA Messersmith et al.
CLINICAL CANCER RESEARCH (2004)
The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
TD Bjornsson et al.
DRUG METABOLISM AND DISPOSITION (2003)
CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans
HM Gonzalez et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the Cooperstown cocktail
DS Streetman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
